North Coast Ventures has made Seed and Acceleration-stage investments in Primum, a healthcare technology company focused on improving cancer care through real-time expert consultation and insight sharing among oncologists.
Primum’s platform connects community oncologists with expert peers for rapid consultation on difficult cases, emerging therapies, and clinical trial opportunities. The result is faster, more informed clinical decision-making that can directly impact patient care.
At the same time, the platform aggregates anonymized inquiry data to surface prescribing patterns, knowledge gaps and referral trends. For biopharma partners, this represents a cost-effective, scalable alternative to traditional advisory boards and a powerful tool for improving engagement strategies.
This dual-sided model addresses a critical need in oncology: timely access to expertise for physicians and actionable insights for industry stakeholders. Early traction reflects strong demand – Primum already counts more than 750 oncologists across 37 states, with 57% of consults resulting in treatment changes. On the industry side, the company has secured recurring contracts with leading pharmaceutical partners, tripling revenue this year and is on track to double again in 2026.
Erica Conroy, PhD, leads Primum as CEO. She brings deep domain expertise from pharmaceutical development and leadership roles at CoverMyMeds. Erica’s background spans cancer drug discovery research as well as developing and scaling fast-growing technology products and businesses that address critical needs in healthcare. She is supported by a board with expertise across medical affairs, health technology, and pharmaceutical strategy — including NCV investor Lance Hill, from Within3.
“I’m thrilled to have the opportunity to work with Lance Hill, whose experience leading Within3 brings invaluable perspective, along with the other incredible leaders on our board,” said Erica. “The fact that North Coast Ventures helped us assemble a team of advisors who not only believe in our mission but also bring the expertise to accelerate our growth is a true testament to the power of their network.”
We believe Primum sits at the intersection of two major shifts in healthcare: the push toward value-based, outcomes-driven care and the demand for real-world data and insights. Its leadership strength, growing oncologist network and positive customer validation position it for long-term success.
While early in its commercialization journey, Primum is aligned with the interests of many NCV subject matter experts in healthcare innovation, clinical workflow, and biopharma strategy – making it a strong fit for both the fund and our broader investor network.
These investments were made through North Coast Ventures Seed Fund V and Acceleration Fund III.
About North Coast Ventures
North Coast Ventures (NCV) is a Cleveland-based early-stage venture capital firm primarily investing in B2B, SaaS companies. With over 500 member investors, NCV is the largest, single-chapter investor group in the country. Since 2006, NCV and its member investors have deployed more than $100M into over 70 high-potential ventures.